Lakefront to present gamgertamig autoimmune cytopenia data at ASH 2026

Lakefront Biotherapeutics NV announced on November 4, 2026 that a poster on its investigational drug gamgertamig will be presented at the American Society of Hematology Annual Meeting, held December 12-15 in New Orleans. The poster, numbered 3008, covers initial global clinical experience with gamgertamig (CM336/OM336), a BCMAxCD3 T-cell engager, in relapsed or refractory autoimmune cytopenias across two ongoing studies registered as NCT07083960 and NCT07175493.¹

The release summarized data from 33 patients with autoimmune cytopenias who received gamgertamig, including 22 with immune thrombocytopenia (ITP) and 11 with autoimmune hemolytic anemia (AIHA), broken out as 9 warm AIHA, 1 cold agglutinin disease, and 1 mixed AIHA.¹ In ITP, 18 of 20 evaluable patients, or 90%, achieved a response defined as a platelet count of at least 30 x 10^9/L and at least double from baseline, with response rates of 2 of 3, 4 of 5, and 12 of 12 patients in the low, mid, and high dose cohorts respectively, and 17 of 18 responders reaching platelet normalization.¹ For AIHA, every evaluable patient in the mid and high dose cohorts responded, defined as a hemoglobin increase of at least 2 g/dL from baseline, representing 6 of 6 and 3 of 3 patients in those cohorts.¹

On safety, Grade 1 cytokine release syndrome occurred in 6 of 33 patients (18%), with no Grade 2 or higher CRS and no cases of ICANS or other neurotoxicity reported; infections occurred in 10 of 33 patients (30%), mostly Grade 1 or 2 and managed successfully.¹

Lakefront also said gamgertamig is expected to enter registrational studies in 2027 and is in-licensed from Keymed Biosciences, which holds development rights for Greater China.¹ The company will hold an investor conference call and webcast on December 14 at 8:00 AM ET to discuss the data.